The new drug 'Aquipta,' an oral migraine treatment, is becoming available in general hospitals in South Korea.

According to industry sources, AbbVie Korea’s Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of the ‘Big 5’ tertiary general hospitals, including Seoul National University, Kangbuk Samsung Hospital, Hallym University Dongtan Sacred Heart Hospital, and Inha University Hospital.

Since its official launch last month, it has expanded indications. Aquipta is drawing attention as the first and only oral treatment option within the same class.

In 2021, the U.S. Food an